Exploration of Angiogenesis in Decompensated Developmental Venous Abnormalities

Developmental Venous Anomaly Clinical Trial

— Explor-AVD  

Official title:

Exploration of Angiogenesis in Decompensated Developmental Venous Abnormalities

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03986853
• Other study ID #: 2017007-F
• Status: Terminated
• Phase: N/A
• Start date: January 11, 2018
• Est. completion date: January 11, 2021

Study information

• Verified date: August 2022
• Source: Hopital Foch
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of our study is to demonstrate by blood samples in situ in the vascular lesion (performed during any cerebral catheterization for an embolization of arteriovenous malformation) the existence of angiogenic growth factors and inflammatory factors that would confirm the decompensation of venous ischemia.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 3
• Est. completion date: January 11, 2021
• Est. primary completion date: January 11, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Main Inclusion Criteria:

• Presenting a DVA requiring hyperselective catheterization

• Having sign an informed consent form

Exclusion Criteria:

• Presenting a contraindication to the realization of hyperselective cathterism

Related Conditions & MeSH terms

• Congenital Abnormalities
• Developmental Venous Anomaly

Intervention

Procedure:
• Blood sampling
Blood sampling under general anesthesia

Locations

Country	Name	City	State
France	Hôpital Foch	Suresnes

Sponsors (2)

Lead Sponsor	Collaborator
Hopital Foch	Collège de France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assessment of angiogenic and inflammatory growth factors	The 1st factor studied is VEGF-A	1 day
Primary	Assessment of angiogenic and inflammatory growth factors	The 2nd factor studied is VEGF-A	1 day
Primary	Assessment of angiogenic and inflammatory growth factors	The 3rd factor studied is angiopoitin-2	1 day
Primary	Assessment of angiogenic and inflammatory growth factors	The 4th factor studied is PDGF	1 day
Primary	Assessment of angiogenic and inflammatory growth factors	The 5th factor studied is angiopoietin-like 4	1 day